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Aims Protocols using sublingual nitrates have been increasingly used to improve diagnostic accuracy of
head-up tilt testing (HUT). Nevertheless, exaggerated responses to nitrates have been frequently
described, particularly in elderly patients. The aim of this article is to evaluate, in an elderly population
with unexplained syncope, whether the impact of sublingual nitroglycerin (NTG) used as a provocative
agent is dose-dependent.
Methods and results One hundred and twenty consecutive elderly patients submitted to HUTusing NTG
after an asymptomatic drug-free phase were studied. Patients were divided into three groups according
to the NTG dosage: 500, 375 and 250 mg. The test was considered positive when there was reproduction
of symptoms with bradycardia and/or arterial hypotension. A gradual decrease in the blood pressure
after NTG was considered an exaggerated response to nitrates. There were no differences in the clinical
characteristics of the different subgroups. A positive test was obtained in 50% of the patients in each
group. The rate of exaggerated responses was identical in all groups and ranged between 15 and 17%.
Conclusion In an elderly population with syncope of unknown origin submitted to HUT, the response to
NTG is not dose-dependent, and no difference was found in the rate of exaggerated responses to






Since its ﬁrst description by Raviele et al.1 in 1994, head-up
tilt testing (HUT) using nitrates as a provocative agent has
been increasingly used. Its main advantage is the fact that
it can be well tolerated (compared with isoproterenol), and
the protocol is more simpliﬁed than the use of isoproterenol.
It can also be more safely used in elderly patients, as, in this
population, there is a contraindication to the use of isoprot-
erenol in up to 10% of the patients.2 It also allows us to inden-
tify exaggerated response to nitrates. In previous studies that
compared younger with elderly patients, an increased preva-
lence of exaggerated responses to nitrates has been
described in the elderly group.3 However, in our own experi-
ence, the incidence of exaggerated responses to nitrates was
similar in both elderly and younger patients.4
Several protocols are being used, with different nitrate
formulations, preparations, and dosages, making them difﬁ-
cult to compare the results between centres.5–7 The results
are considered good for most of the protocols proposed, but
slightly different from each other. Additionally, there is lack
of data if responses are dose-dependent.
It was our objective to analyse, in a population of elderly
patients with syncope of unknown aetiology, whether the
impact of sublingual nitroglycerin (NTG), as a provocative
agent in HUT, is dose-dependent.
Patients and methods
The prospective study includes 120 consecutive elderly patients
(65 years), submitted to HUT using sublingual NTG. Only patients
with an asymptomatic drug-free phase of the test were included
in the study (81%) out of a total of 149 elderly patients submitted
to HUT in the same period. Patients with very typical precipitating
factors or prodromal symptoms for syncope were not included in
this study.
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All patients underwent a standard evaluation to exclude other
causes of syncope: clinical history and physical examination (includ-
ing neurological evaluation), routine blood tests, 12-lead ECG, 24 h
Holter monitoring, transthoracic echocardiography, stress testing,
and carotid ultrasound. When this complete evaluation was negative
and the aetiology for the syncope remained unknown, the patient
was referred for HUT. Patients underwent HUT in a fasting state
(4–6 h) between 11 am and 2 pm. Beta-blockers and nitrates were
stopped for at least 48 h. An automatic tilt table was used with con-
tinuous monitoring of heart rate and blood pressure with a Task
Force Monitor (CNSystemsTM).
A modiﬁed Italian Protocol was used.6 The ﬁrst change was the
use of intravenous cannulation. As this can inﬂuence the speciﬁcity
of the test, the stabilization phase was prolonged to 30 min to
achieve a stable condition of the patient. The other difference
was the use of a 708 tilt angle. After the stabilization phase,
carotid sinus massage was performed to test for carotid sinus hyper-
sensitivity. Then, the patient was tilted to 708 and the carotid sinus
massage was performed again in the upright position. Further, we
moved on to the passive phase (20 min). When this phase was nega-
tive, the patient received sublingual NTG and underwent a provoca-
tive phase for another 20 min, followed by the recovery phase. The
test was interrupted after the completion of the protocol in the
absence of symptoms or if syncope occurred.
Syncope was deﬁned as a sudden transient loss of consciousness
with inability to maintain postural tone and with spontaneous recov-
ery. A positive test was deﬁned as reproduction of the spontaneous
syncope in association with bradycardia (decrease in heart rate
.30% of the maximum value observed in the upright position),
hypotension (decrease in the systolic blood pressure .50% of the
maximal value observed in the upright position), or both, with
rapid onset (occurring within 5 min), and classiﬁed according to
the classical VASIS classiﬁcation of neurocardiogenic responses: car-
dioinhibitory, vasodepressive, or mixed.8 An exaggerated response
to nitrates was deﬁned as a gradual development of symptoms, as
a consequence of progressive and slow (occurring in .5 min)
decrease in blood pressure along with only a slight reduction
(,30%) or no change in the heart rate.1
To test our hypothesis, three different NTG dosages were tested.
The ﬁrst 20 consecutive elderly patients received 500 mg, followed
by 20 patients receiving 250 mg and 20 patients receiving 375 mg.
This process was repeated in the same sequence, until 40 patients
were included in each group. Heart rate and blood pressure in the
basal state (with tilting at 708) and 5 min after sublingual NTG
(time considered for the complete absorption of the sublingual
NTG tablet) were also compared.
The study complies with the Declaration of Helsinki, and informed
consent was obtained from all the patients.
Statistical analysis
Continuous variables were expressed as mean+ SD and categorical
variables as frequencies and percentages. Continuous variables
were compared with the two-tailed Student’s t-test. Categorical
variables were compared with the x2 test/Fisher’s test, as appropri-
ate, to compare all the groups. A P-value less than 0.05 was con-
sidered statistically signiﬁcant.
Results
Groups had an identical distribution for the clinical charac-
teristics (Table 1). Most patients had no structural heart
disease, and the distribution of hypertension and stable
chronic ischaemic heart disease was identical. Most patients
did not receive any previous cardiac medication. Some were
on beta-blockers, ACE inhibitors, or nitrates, but there were
no statistically signiﬁcant differences between groups in the
type of medication received.
The test was positive in 50% of the patients. Exaggerated
responses to nitrates ranged between 15 and 17%. Vaso-
depressive neurocardiogenic type of response was more
commonly observed (45–60%), followed by a mixed response
(30–45%) and a cardioinhibitory response (5–15%) (Table 2).
There were also no statistically signiﬁcant differences
between different age groups (Table 3).
When blood pressure and heart rate were compared at
basal conditions and at the peak effect of NTG (5 min
after sublingual administration), there were some differ-
ences in terms of systolic blood pressure between 500 and
375 mg and between 500 and 250 mg (Table 4). No differ-
ences were found in the diastolic blood pressure and heart
rate. However, the average change in the systolic blood
pressure and heart rate was signiﬁcantly lower in the
group that received 250 mg, suggesting that the effect of
NTG on blood pressure and heart rate is dose-dependent.
Discussion
After its introduction by Raviele et al.,1 HUT protocols with
nitrates have been replacing isoproterenol as a provocative
agent with similar accuracy, better tolerance, and without
serious side effects. In fact, isoproterenol is contraindicated
in patients with coronary artery disease, aortic stenosis, and








Age (years) 73+ 6 75+ 6 72+ 8 NS
Female gender 55 50 60 NS
Without heart
disease
59 66 60 NS
Hypertensive
heart disease
27 28 30 NS
Ischaemic heart
disease
14 6 10 NS
Previous
medication
Beta-blockers 19 11 17 NS
ACEI 18 17 10 NS
Nitrates 6 3 4 NS
No cardiac
medication
57 55 60 NS
ACEI, angiotensin-converting enzyme inhibitor.
Table 2 Responses obtained during head-up tilt testing







Negative test 13 (33) 14 (35) 13 (33) NS
Exaggerated
response
7 (17) 6 (15) 7 (17) NS
Positive test 20 (50) 20 (50) 20 (50) NS
Vasodepressive 12 (60) 9 (45) 10 (50) NS
Cardioinhibitory 2 (10) 3 (15) 1 (5) NS
Mixed 6 (30) 8 (40) 9 (45) NS
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severe hypertension, compromising its use in almost 10% of
the patients mainly in an elderly population.2 Isoproterenol
can cause ventricular arrhythmias and angina pectoris in up
to 18% of the patients submitted to HUT.1,9 With nitrates,
the main side effect described is headache without serious
complications. This makes nitrates the ideal provocative
agent to be used in elderly patients.
Although intravenous NTG is well tolerated, it requires
venous cannulation (with a prolonged stabilization phase)
and it is more technically demanding. To simplify the test,
Raviele et al.10 introduced sublingual NTG in 1995 as an
alternative with similar accuracy for the diagnosis of
syncope. This protocol was further simpliﬁed in subsequent
studies, by shortening the passive phase.11,12 Because each
centre adopted different protocols, Bartoletti et al.,6 in
an attempt to standardize the test, described the ‘Italian
Protocol’. For the same purpose, the European Society of
Cardiology described the recommended protocol in the
‘Syncope Guidelines’ updated in 2004.2
The ﬁrst study comparing results in elderly and younger
patients, obtained a positive rate of 66% in the elderly and
60% in the younger patients.3 However, according to the
same author, the exaggerated response was more commonly
observed in the elderly (11 vs. 1%) using 400 mg of sublingual
NTG spray. Other studies showed a rate of exaggerated
responses in the elderly similar to that described in
younger patients.4,13–16 However, results are difﬁcult to
compare because each centre uses not only different proto-
cols (tilt angle, passive and stimulated phase duration)
but also different nitrate formulations, preparations, and
dosages.5,6 These different dosages and types of adminis-
tration are responsible for different rates of absorption
and bioavailability of nitrates. In two recently published
reviews, positive rates during HUT ranged from 51 to 78%
and exaggerated responses from 4 to 21%.5,6 This had
implications in the range of sensitivity (35–87%), speciﬁcity
(63–100%), and accuracy (56–81%) obtained with HUT.
Although we believed that different nitrate dosages could
inﬂuence the HUT results, it was not possible to obtain con-
clusive answers from the published data. In our country, the
formulation available for NTG is 500 mg tablets. Our study
was designed to study the inﬂuence of nitrate dosage on
the results of the HUT. All patients underwent the same
protocol, with changes only in the NTG dosage.
Because of its potent vasodilatory effect in the capacity
vessels (by indirect stimulation of GMPc, causing relaxation
of vascular smooth muscle), nitrates signiﬁcantly increase
venous pooling (in the lower limbs, viscera, and mesentery)
already enhanced by the upright posture. The reduction in
venous return, ventricular volume, and cardiac output
induces a reﬂex increase in the sympathetic tone with con-
sequent vigorous contraction of the heart. In predisposed
patients, this leads to a paradoxical activation of the ventri-
cular mechano-receptors with inhibitory afferents to cardio-
vascular brainstem centres, which are ultimately responsible
for the triggering of Bezold–Jarish reﬂex with vasodilation,
bradycardia, hypotension, and syncope.5 However, the
precise mechanism by which nitrates increase the sensitivity
of the test may be more complex than the widely assumed
venodilating phenomenon. In fact, in our study, the systolic
blood pressure was slightly different between groups after
NTG, with the lowest systolic blood pressure in the 500 mg
group and the highest in the 250 mg group. The average
change in the systolic blood pressure and heart rate was
also signiﬁcantly lower in the group that received 250 mg,
suggesting that the effect of NTG on blood pressure and
heart rate is dose-dependent. But according to our results,
NTG dosage does not seem to inﬂuence the paradoxical acti-
vation of the Bezold–Jarish reﬂex. Nitrates are lipid soluble
and readily cross the blood-to-brain barrier in humans,
which potentially makes the central action an additional
pathway of nitrate-induced syncope.5 Other factors such
as neurohumoral activation could also contribute either










120+ 10 133+ 17 126+ 16
Basal DBP (mmHg) 81+ 10 81+ 13 84+ 12
Basal HR (bpm) 73+ 14 72+ 14 71+ 14
Peak NTG SBP
(mmHg)a,b
107+ 16 118+ 24 121+ 28
Peak NTG DBP
(mmHg)
72+ 11 77+ 16 76+ 16
Peak NTG HR (bpm) 86+ 16 84+ 18 83+ 18
DSBP (basal-peak)
(mmHg)b,c
213+ 20 215+ 20 25 + 15
DDBP (basal-peak)
(mmHg)
29+ 16 24 + 14 28 + 16
DHR (basal-peak)
(bpm)b,c
þ13+ 12 þ12+ 20 þ2 + 12
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart
rate; D, average change; NTG, nitroglycerin.
aP , 0.05 (500 vs. 375 mg).
bP , 0.05 (500 vs. 250 mg).
cP , 0.05 (375 vs. 250 mg).
Table 3 Responses obtained during head-up tilt testing by age groups
Age groups (years) 500 mg 375 mg 250 mg
65–75 n ¼ 24 .75 n ¼ 16 65–75 n ¼ 20 .75 n ¼ 20 65–75 n ¼ 24 .75 n ¼ 16
Positive test, n (%) 13 (54) 7 (44) 10 (50) 10 (50) 13 (54) 7 (44)
Negative test, n (%) 7 (29) 6 (37) 7 (35) 7 (35) 8 (33) 13 (31)
Exaggerated response, n (%) 4 (17) 3 (19) 3 (15) 3 (15) 3 (13) 4 (25)
P-value¼non-signiﬁcant for all comparisons.
HUTwith different nitroglycerin dosages 1093








directly or indirectly to the vaso-vagal cascade through the
baro-reﬂex.5 These hypotheses can suggest an explanation
underlying different mechanisms associated with a response
to nitrates that might not be dose-dependent.
Exaggerated responses to nitrates are usually considered
as a manifestation of an excessive vasodilation produced
by NTG and not as secondary to the triggering of neural
reﬂex. In our work, the incidence of this type of response
was identical in all three groups and does not seem to be
dose-dependent also. We can hypothesize that other mech-
anisms of action of nitrates might be involved in this type of
response. A detailed study of the autonomous nervous
system changes by spectral analysis, neurohumoral beha-
viour, or other potential mechanisms in this particular popu-
lation of patients could be performed to give some insight
into this subject.
The overall rate of positive tests for neurocardiogenic
responses was 50%, slightly lower than those reported by
other authors.3,10–14 However, in our study, we did not con-
sider passive phase results, as patients with a diagnosis
obtained in this phase were not included in the study. This
represents 10–20% of the HUT results in other studies,
and it was 19% in our experience.3,7,14
In our population, most patients had a vasodepressive
response followed by the mixed response, which is in accord-
ance with other authors.3,13–16 In fact, Kochiadakis et al.15
performed a detailed study of autonomic activity during
HUTand concluded that autonomic nervous system behaviour
was similar in older and younger patients, suggesting that the
mechanism responsible for vasovagal syncope is basically the
same in both the groups. Nevertheless, although a reduction
of sympathetic activity in response to tilting was observed in
both groups, it was greater in elderly patients, which may
explain the subsequent vasodilation in these patients. In con-
trast, parasympathetic system activation immediately prior
to syncope occurred less in elderly than in younger patients,
which may explain the low incidence of marked bradycardia
in the elderly.
Limitations
One limitation of the present study is the fact that the
results cannot be generalized to formulations other than
NTG tablets, because the spray has a different rate of
absorption and bioavailability. Another limitation is the
fact that we do not have a control group that could be
used to evaluate sensitivity and speciﬁcity with different
NTG dosages. However, our results are similar to other pre-
viously reported in terms of positivity rate of the HUT with
nitrates.5,6 Finally, it seems that the results are similar in
different age groups (65–75 and .75 years) and NTG
dosages. However, the small number of patients in each sub-
group is a statistical limitation for an adequate statistical
analysis.
Conclusion
In a population of elderly patients with syncope of unknown
origin submitted to HUT potentiated by sublingual NTG, the
response to nitrates is not dose-dependent, and no
difference was found in terms of the rate of exaggerated
responses to nitrates. Head-up tilt testing is a safe test,
and using sublingual NTG as a provocative agent provides
a signiﬁcant contribution to the aetiological diagnosis of
syncope in patients with a negative passive test.
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